SlamonD.J., ClarkG.M., WongS.G.. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene.Science.1987; 235: 177–182.
2.
PressM.G., BernsteinL., ThomasP.A.. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.J Clin Oncol.1997; 15: 2894–2904.
3.
PegramM.D., FinnR.S., ArzooK.. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cells.Oncogene.1997; 15: 537–547.
4.
PlunkettT.A., HoustonS.J., RubensR.D.. Her-2 overexpression is a marker of resistance to endocrine therapy in advanced breast cancer.Breast Cancer Treat.1998; 50: 238. Abstract.
5.
ElledgeR.M., GreenS., CioccaD.. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group study.Clin Cancer Res.1998; 4: 7–12.
6.
BiancoA.R., DeLaurentiisM., CarlomagnoC.. 20-year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-erb-B2 expression and tamoxifen efficacy.Proc Annu Meet Am Soc Clin Oncol.1998; 17: 97a. Abstract.
7.
MussH.B., ThorA.D., BerryD.A.. HER2 expression and response to adjuvant therapy in women with node positive early breast cancer.N Engl J Med.1994; 330: 1260–1266.
8.
ThorA.D., BerryD.A., BudmanD.R.. erbB2, p53, and the efficacy of adjuvant therapy in lymph node positive breast cancer.J Natl Cancer Inst.1998; 90: 1346–1360.
9.
PaikS., BryantJ., ParkC.. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive hormone receptor-negative breast cancer.J Natl Cancer Inst.1998; 90: 1361–1370.
10.
BaselgaJ., TripathyD., MendelsohnJ.. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.J Clin Oncol.1996; 14: 737–744.
11.
CobleighM.A., VogelC.L., TripathyN.J.. Efficacy and safety of Herceptin (humanized anti-Her-2 antibody) as a single agent in 222 women with Her-2 overexpression who relapsed following chemotherapy for metastatic breast cancer.Proc Annu Meet Am Soc Clin Oncol.1998; 17: 97a. Abstract.
12.
SlamonD., Leyland-JonesB., ShakS.. Addition of Herceptin (humanized anti-Her-2 antibody) to first-line chemotherapy for Her-2 overexpressing metastatic breast cancer (Her2 ± MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial.Proc Annu Meet Am Soc Clin Oncol.1998; 17: 98a. Abstract.
